Low Dose Buprenorphine Initiation: A Guide for the Inpatient Clinician.

IF 2.8 3区 医学 Q2 SUBSTANCE ABUSE
Substance abuse Pub Date : 2023-07-01 Epub Date: 2023-09-20 DOI:10.1177/08897077231196417
Cara Zimmerman, Seth Clark, Michael E Guerra, Jeffrey Bratberg, Kathleen K Adams
{"title":"Low Dose Buprenorphine Initiation: A Guide for the Inpatient Clinician.","authors":"Cara Zimmerman,&nbsp;Seth Clark,&nbsp;Michael E Guerra,&nbsp;Jeffrey Bratberg,&nbsp;Kathleen K Adams","doi":"10.1177/08897077231196417","DOIUrl":null,"url":null,"abstract":"<p><p>Low dose buprenorphine initiation (LDBI) is a dosing strategy used to transition patients from full opioid agonists to buprenorphine. The purpose of LDBI is to circumvent obstacles associated with disruption in analgesia, precipitated withdrawal, and prerequisite opioid withdrawal prior to initiating buprenorphine, as not all patients are able to tolerate physical withdrawal symptoms recommended by national guidelines. No literature exists directly comparing traditional buprenorphine initiation to LDBI. Until information on long-term outcomes is available, these dosing strategies should be reserved for patients unable to tolerate traditional buprenorphine initiation. Available published research suggests LDBI strategies will allow some patients to successfully transition to buprenorphine with minimal or no symptoms of withdrawal. Ensuring access to pharmacotherapy during hospital admission is a crucial time for potential intervention and should be considered when appropriate. This narrative review discusses the background of LDBI strategies as well as practical clinical and operational considerations for the inpatient clinician.</p>","PeriodicalId":22108,"journal":{"name":"Substance abuse","volume":"44 3","pages":"121-129"},"PeriodicalIF":2.8000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Substance abuse","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/08897077231196417","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0

Abstract

Low dose buprenorphine initiation (LDBI) is a dosing strategy used to transition patients from full opioid agonists to buprenorphine. The purpose of LDBI is to circumvent obstacles associated with disruption in analgesia, precipitated withdrawal, and prerequisite opioid withdrawal prior to initiating buprenorphine, as not all patients are able to tolerate physical withdrawal symptoms recommended by national guidelines. No literature exists directly comparing traditional buprenorphine initiation to LDBI. Until information on long-term outcomes is available, these dosing strategies should be reserved for patients unable to tolerate traditional buprenorphine initiation. Available published research suggests LDBI strategies will allow some patients to successfully transition to buprenorphine with minimal or no symptoms of withdrawal. Ensuring access to pharmacotherapy during hospital admission is a crucial time for potential intervention and should be considered when appropriate. This narrative review discusses the background of LDBI strategies as well as practical clinical and operational considerations for the inpatient clinician.

低剂量丁丙诺啡引发:住院临床医生指南。
低剂量丁丙诺啡引发(LDBI)是一种用于将患者从全阿片类激动剂转变为丁丙诺芬的给药策略。LDBI的目的是在开始丁丙诺啡之前绕过与镇痛中断、急性戒断和先决条件阿片类药物戒断相关的障碍,因为并非所有患者都能耐受国家指南建议的身体戒断症状。没有文献直接将传统丁丙诺啡引发与LDBI进行比较。在获得长期结果的信息之前,这些给药策略应保留给无法耐受传统丁丙诺啡给药的患者。现有已发表的研究表明,LDBI策略将使一些患者成功过渡到丁丙诺啡,而戒断症状很小或没有。确保在入院期间获得药物治疗是潜在干预的关键时刻,应在适当的时候予以考虑。这篇叙述性综述讨论了LDBI策略的背景以及住院临床医生的实际临床和操作注意事项。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Substance abuse
Substance abuse SUBSTANCE ABUSE-
CiteScore
5.90
自引率
2.90%
发文量
88
审稿时长
>12 weeks
期刊介绍: Now in its 4th decade of publication, Substance Abuse journal is a peer-reviewed journal that serves as the official publication of Association for Medical Education and Research in Substance Abuse (AMERSA) in association with The International Society of Addiction Medicine (ISAM) and the International Coalition for Addiction Studies in Education (INCASE). Substance Abuse journal offers wide-ranging coverage for healthcare professionals, addiction specialists and others engaged in research, education, clinical care, and service delivery and evaluation. It features articles on a variety of topics, including: Interdisciplinary addiction research, education, and treatment Clinical trial, epidemiology, health services, and translation addiction research Implementation science related to addiction Innovations and subsequent outcomes in addiction education Addiction policy and opinion International addiction topics Clinical care regarding addictions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信